Premium
Is pharmacotherapy feasible for mild cognitive impairment?
Author(s) -
SHIGETA Masahiro
Publication year - 2005
Publication title -
psychogeriatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.647
H-Index - 32
eISSN - 1479-8301
pISSN - 1346-3500
DOI - 10.1111/j.1479-8301.2005.00100.x
Subject(s) - clinical trial , pharmacotherapy , cognitive impairment , medicine , inclusion and exclusion criteria , cholinesterase , cognition , disease , drug trial , alzheimer's disease , psychology , psychiatry , pathology , alternative medicine
The feasibility of pharmacotherapy with cholinesterase inhibitors, which have been approved as the treatment agent for Alzheimer's disease (AD), for mild cognitive impairment (MCI) is discussed together with the results of previous studies. The clinical trials of cholinesterase inhibitors in patients with early or mild AD are reviewed first, because some cases of MCI may be regarded as cases of very early‐stage AD or very mild AD. Clinical trials for MCI treatment are then analyzed, although only preliminary results of data analysis have been reported. In addition, the methodological issues in the clinical trials for MCI treatment are discussed. The author points out that there should be focus on the observation period of trials, patient inclusion and exclusion criteria and subtypes of MCI, and that the suitability of cognitive measurements need to be further discussed.